Lipids in Parenteral Nutrition: Biological Aspects
Carregando...
Citações na Scopus
65
Tipo de produção
article
Data de publicação
2020
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
Citação
JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, v.44, suppl.1, Special Issue, p.S21-S27, 2020
Resumo
Lipid emulsions are an integral part of parenteral nutrition, and traditionally have been regarded as an energy-dense source of calories and essential fatty acids. For many years, lipids used in parenteral nutrition have been based on vegetable oils (eg, soybean-oil emulsions). However, soybean-oil emulsions may not have an optimal fatty-acid composition under some circumstances when used as the only lipid source, as soybean oil is particularly abundant in the omega-6 polyunsaturated fatty acid (PUFA), linoleic acid. Hence, a progressive series of more complex lipid emulsions have been introduced, typically combining soybean oil with 1 or more alternative oils, such as medium-chain triglycerides (MCTs) and/or olive oil and/or fish oil. The wide range of lipid emulsions now available for parenteral nutrition offers opportunities to alter the supply of different fatty acids, which potentially modifies functional properties, with effects on inflammatory processes, immune response, and hepatic metabolism. Fish oil has become an important component of modern, composite lipid emulsions, in part owing to a growing evidence base concerning its biological effects in a variety of preclinical models. These biological activities of fish oil are mainly attributed to its omega-3 PUFA content, particularly docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). DHA and EPA have known mechanisms of action, anti-inflammatory, immunomodulatory, and antioxidative properties. Specialized proresolving mediators, such as resolvins, protectins, and maresins, are synthesized directly from DHA and EPA, are key for the resolution of inflammation, and improve outcomes in many cell- and animal-based models and, recently, in some clinical settings.
Palavras-chave
fatty acids, fish oil, immunomodulation, inflammation, lipids, omega-3 fatty acids, parenteral nutrition, soybean oil, specialized pro-resolving mediator
Referências
- BABAYAN VK, 1987, LIPIDS, V22, P417, DOI 10.1007/BF02537271
- Bertevello PL, 2012, JPEN-PARENTER ENTER, V36, P442, DOI 10.1177/0148607111421788
- Buenestado A, 2006, JPEN-PARENTER ENTER, V30, P286, DOI 10.1177/0148607106030004286
- Calder PC, 2006, P NUTR SOC, V65, P264, DOI 10.1079/PNS2006500
- Calder PC, 2019, MAR DRUGS, V17, DOI 10.3390/md17050274
- Calder PC, 2018, CLIN NUTR, V37, P1, DOI 10.1016/j.clnu.2017.08.032
- Calder PC, 2015, JPEN-PARENTER ENTER, V39, p18S, DOI 10.1177/0148607115595980
- Calder PC, 2013, P NUTR SOC, V72, P263, DOI 10.1017/S0029665113001250
- Calder PC, 2013, BRIT J CLIN PHARMACO, V75, P645, DOI 10.1111/j.1365-2125.2012.04374.x
- Calder PC, 2012, J NUTR, V142, p592S, DOI 10.3945/jn.111.155259
- Calder PC, 2010, INTENS CARE MED, V36, P735, DOI 10.1007/s00134-009-1744-5
- Fell GL, 2015, ADV NUTR, V6, P600, DOI 10.3945/an.115.009084
- Klek S, 2016, J CLIN MED, V5, DOI 10.3390/jcm5030034
- Martindale RG, 2019, JPEN J PARENTER ENTE
- Norris PC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36679-4
- Pradelli L, JPEN J PARENTER ENTE
- Pradelli L, 2012, CRIT CARE, V16, DOI 10.1186/cc11668
- Raman M, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040388
- Sansbury BE, 2016, CIRC RES, V119, P113, DOI 10.1161/CIRCRESAHA.116.307308
- Serhan CN, 2018, J CLIN INVEST, V128, P2657, DOI 10.1172/JCI97943
- Serhan CN, 2015, BBA-MOL CELL BIOL L, V1851, P397, DOI 10.1016/j.bbalip.2014.08.006
- Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479
- Serhan CN, 2011, CHEM REV, V111, P5922, DOI 10.1021/cr100396c
- Sugimoto MA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00160
- Waitzberg DL, 2006, JPEN-PARENTER ENTER, V30, P351, DOI 10.1177/0148607106030004351
- Waitzberg DL, 2015, WORLD REV NUTR DIET, V112, P150, DOI 10.1159/000365609
- Wanten GJA, 2007, AM J CLIN NUTR, V85, P1171